Assessment of the association between prognosis and therapeutic response to Nivolumab and the expression of transforming growth factor-beta-induced protein (TGFBI), intratumoral immune cells including CD8- and Forkhead box protein P3 (Foxp3)-positive T cells in patients with recurrent advanced Non-small Cell Lung Cancer
Latest Information Update: 10 Dec 2020
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 10 Dec 2020 New trial record